Harry Zhabilov

 

Harry Zhabilov - Professional Summary:    Possessing a Master’s degree in Chemistry and Biochemistry, Harry Zhabilov accepted a position in the biotechnology and pharmaceutical industries. Currently the Executive Vice President of Research and Development of Immunotech Laboratories, Harry Zhabilov utilizes his background in science to manage the operations of the biotech company. A publicly traded company, Immunotech Laboratories concentrates on exploring and creating IPF (irreversible pepsin fraction) to aid in treatment and detection of immune and viral diseases. Harry Zhabilov utilizes his extensive knowledge in biochemical research to help individuals through Immunotech Laboratories’ mission to manufacture proteins used in various treatments of incapacitating, transmittable diseases. Harry Zhabilov assisted in launching the company's flagship compound ITV-1 (Immune Therapeutic Vaccine-1). In a suspension of Inactive Pepsin Fraction (IPF), analysis of the vaccine reveals it to be an effective factor in treating HIV and AIDS by stabilizing the immune system. He summarized the findings of ITV-1 in a published paper titled “Immune Therapeutic Vaccine (ITV): A Fusion Inhibitor and Immunomodulator." In addition to his role as Executive Vice President, Harry Zhabilov also serves as Immunotech Laboratories’ Chief Science Officer. He leads the Immunotech Laboratories team in discovering new, applications of IPF. A proprietary platform technology, IPF is a unique suspension that differs from its contemporary anti-retrovirals since it possesses no gastrointestinal, neurological, and hematological side effects. Additionally, as a contributor to the development of IPF, Harry Zhabilov has aided in increasing business revenue for the company.

 

 

Harry Zhabilov - Professional Experience:    

 

Immunotech Laboratories

Executive Vice President Research and Development Secretary Vice Chairman

Biotech/pharmaceutical

Glendale, CA US

 

Immunotech Laboratories publicly traded Research and Development company is focusing on developing IPF (irreversible pepsin fraction) for treatment and screening of the viral and immune disease.

 

 

 

Harry Zhabilov - Education:   Masters in Bio Chemistry

 

 

Harry Zhabilov - LookupPage

Harry Zhabilov on Businesscard 2

Harry Zhabilov on Xing

Harry Zhabilov on Linked In

Harry Zhabilov on Tumblr